Finding 393896 (2023-010)

Material Weakness
Requirement
H
Questioned Costs
$1
Year
2023
Accepted
2024-04-22
Audit: 304072
Organization: YWCA West Central Michigan (MI)

AI Summary

  • Core Issue: The Organization failed to manage cash and period of performance effectively, leading to compliance findings and significant deficiencies in internal controls.
  • Impacted Requirements: Non-compliance with 2 CFR 200.305 regarding timely disbursement of federal funds and proper allocation of costs within the approved budget period.
  • Recommended Follow-Up: Implement procedures to ensure timely payments to vendors and accurate recording of expenditures within the correct grant periods.

Finding Text

U.S. Department of Justice Crime Victim Assistance – Assistance #16.575 #2023-009 – Major Federal Award Finding – Cash Management Nature of Finding: Compliance Finding Cash Management and Significant Deficiency in Internal Controls over Compliance Criteria/Condition: 2 CFR 200.305 requires that non-federal entities must minimize the time elapsing between the transfer of federal funds to the non-federal entity and the subsequent disbursement of the funds by the non-federal entity for program costs. The Organization did not have proper controls in place to verify that specific vendor invoices were paid within a reasonable amount of time of requesting reimbursement for the expenditures. Questioned Costs: $2,381 Identification of How Questioned Costs Were Computed: The issues of noncompliance related to cash management was limited to one vendor that was not paid within a reasonable amount of time of being reimbursed for the costs. This was determined to be an isolated incident. Questioned costs include the two invoices that were charged to the grant for this vendor during the year ended September 30, 2023 and were not paid to the vendor within a reasonable amount of time of being reimbursed for the expenditures. Cause/Context: Controls were not in place to ensure expenditures were paid to the vendor prior to requesting reimbursements. This circumstance was determined to be an isolated incident due to the unique nature of the vendor invoices. The Organization was withholding payment to the vendor until it determined that both invoices were proper. Effect: The lack of controls could result in requests for reimbursement being submitted for unpaid expenditures. Recommendation: We recommend the Organization establish procedures and incorporate controls to review that expenditures are paid prior to submitting requests for reimbursement. Views of Responsible Officials and Planned Corrective Actions: The Organization will implement the following changes in its accounting procedures: Each month, an aged open accounts payable report will be produced as part of the month end closing. Invoices that are past due will be paid in the following batch of payments (which are typically run weekly). If it is determined that the invoice is not being paid for a valid reason, it will be removed from accounts payable at that time. #2023-010 – Major Federal Award Finding – Period of Performance Nature of Finding: Compliance Finding Period of Performance and Material Weakness in Internal Controls over Compliance Criteria/Condition: A non-federal entity may charge only allowable costs incurred during the approved budget period of a federal award’s period of performance. The Organization did not have controls in place to verify that costs were being charged to the award in the correct period of performance. Questioned Costs: $20,790 Identification of How Questioned Costs Were Computed: A sample of 40 non-payroll expenditures totaling approximately $48,000 was selected from a population of approximately $552,000 of non-payroll expenditures. An amount of $1,817 combined from two invoices that were charged to the Crime Victim Assistance program was related to the year ending September 30, 2024 and was inappropriately charged to the grant during 2023. Questioned costs are estimated by projecting the error identified in the sample tested to the population of non-payroll expenditures of the Crime Victim Assistance program. Cause/Context: There are not proper controls in place to review invoices and assign them to the appropriate grant period. Two expenditures out of forty non-payroll related expenditures tested for the Crime Victim Assistance grant was for a contracted annual service that covered multiple performance periods but was billed in its entirety to the current fiscal year. Effect: An overstatement of expenditures for the Crime Victim Assistance grant was reported in the current year. Recommendation: We recommend procedures are established to review for proper grant period when recording transactions and creating monthly reimbursement requests. Views of Responsible Officials and Planned Corrective Actions: The Organization will implement the following changes in its accounting procedures. 1. The Staff Accountant will review the period each expenditure is related to and record the invoice to the appropriate period when entering it into accounts payable. The month and year will be noted on the invoice. 2. The CFO will review the month and year noted by the Staff Accountant prior to entry into accounts payable.

Categories

Questioned Costs Cash Management Period of Performance Allowable Costs / Cost Principles Material Weakness Significant Deficiency Matching / Level of Effort / Earmarking

Other Findings in this Audit

  • 393863 2023-005
    Significant Deficiency Repeat
  • 393864 2023-006
    Material Weakness
  • 393865 2023-007
    Significant Deficiency
  • 393866 2023-005
    Significant Deficiency Repeat
  • 393867 2023-006
    Material Weakness
  • 393868 2023-007
    Significant Deficiency
  • 393869 2023-005
    Significant Deficiency Repeat
  • 393870 2023-006
    Material Weakness
  • 393871 2023-007
    Significant Deficiency
  • 393872 2023-005
    Significant Deficiency Repeat
  • 393873 2023-006
    Material Weakness
  • 393874 2023-007
    Significant Deficiency
  • 393875 2023-011
    Significant Deficiency Repeat
  • 393876 2023-011
    Significant Deficiency Repeat
  • 393877 2023-011
    Significant Deficiency Repeat
  • 393878 2023-008
    Material Weakness Repeat
  • 393879 2023-009
    Significant Deficiency
  • 393880 2023-010
    Material Weakness
  • 393881 2023-011
    Significant Deficiency Repeat
  • 393882 2023-008
    Material Weakness Repeat
  • 393883 2023-009
    Significant Deficiency
  • 393884 2023-010
    Material Weakness
  • 393885 2023-011
    Significant Deficiency Repeat
  • 393886 2023-008
    Material Weakness Repeat
  • 393887 2023-009
    Significant Deficiency
  • 393888 2023-010
    Material Weakness
  • 393889 2023-011
    Significant Deficiency Repeat
  • 393890 2023-008
    Material Weakness Repeat
  • 393891 2023-009
    Significant Deficiency
  • 393892 2023-010
    Material Weakness
  • 393893 2023-011
    Significant Deficiency Repeat
  • 393894 2023-008
    Material Weakness Repeat
  • 393895 2023-009
    Significant Deficiency
  • 393897 2023-011
    Significant Deficiency Repeat
  • 393898 2023-008
    Material Weakness Repeat
  • 393899 2023-009
    Significant Deficiency
  • 393900 2023-010
    Material Weakness
  • 393901 2023-011
    Significant Deficiency Repeat
  • 393902 2023-011
    Significant Deficiency Repeat
  • 393903 2023-011
    Significant Deficiency Repeat
  • 393904 2023-011
    Significant Deficiency Repeat
  • 393905 2023-011
    Significant Deficiency Repeat
  • 393906 2023-011
    Significant Deficiency Repeat
  • 393907 2023-004
    Material Weakness
  • 393908 2023-004
    Material Weakness
  • 393909 2023-004
    Material Weakness
  • 393910 2023-004
    Material Weakness
  • 393911 2023-004
    Material Weakness
  • 393912 2023-004
    Material Weakness
  • 393913 2023-004
    Material Weakness
  • 393914 2023-004
    Material Weakness
  • 393915 2023-004
    Material Weakness
  • 393916 2023-004
    Material Weakness
  • 970305 2023-005
    Significant Deficiency Repeat
  • 970306 2023-006
    Material Weakness
  • 970307 2023-007
    Significant Deficiency
  • 970308 2023-005
    Significant Deficiency Repeat
  • 970309 2023-006
    Material Weakness
  • 970310 2023-007
    Significant Deficiency
  • 970311 2023-005
    Significant Deficiency Repeat
  • 970312 2023-006
    Material Weakness
  • 970313 2023-007
    Significant Deficiency
  • 970314 2023-005
    Significant Deficiency Repeat
  • 970315 2023-006
    Material Weakness
  • 970316 2023-007
    Significant Deficiency
  • 970317 2023-011
    Significant Deficiency Repeat
  • 970318 2023-011
    Significant Deficiency Repeat
  • 970319 2023-011
    Significant Deficiency Repeat
  • 970320 2023-008
    Material Weakness Repeat
  • 970321 2023-009
    Significant Deficiency
  • 970322 2023-010
    Material Weakness
  • 970323 2023-011
    Significant Deficiency Repeat
  • 970324 2023-008
    Material Weakness Repeat
  • 970325 2023-009
    Significant Deficiency
  • 970326 2023-010
    Material Weakness
  • 970327 2023-011
    Significant Deficiency Repeat
  • 970328 2023-008
    Material Weakness Repeat
  • 970329 2023-009
    Significant Deficiency
  • 970330 2023-010
    Material Weakness
  • 970331 2023-011
    Significant Deficiency Repeat
  • 970332 2023-008
    Material Weakness Repeat
  • 970333 2023-009
    Significant Deficiency
  • 970334 2023-010
    Material Weakness
  • 970335 2023-011
    Significant Deficiency Repeat
  • 970336 2023-008
    Material Weakness Repeat
  • 970337 2023-009
    Significant Deficiency
  • 970338 2023-010
    Material Weakness
  • 970339 2023-011
    Significant Deficiency Repeat
  • 970340 2023-008
    Material Weakness Repeat
  • 970341 2023-009
    Significant Deficiency
  • 970342 2023-010
    Material Weakness
  • 970343 2023-011
    Significant Deficiency Repeat
  • 970344 2023-011
    Significant Deficiency Repeat
  • 970345 2023-011
    Significant Deficiency Repeat
  • 970346 2023-011
    Significant Deficiency Repeat
  • 970347 2023-011
    Significant Deficiency Repeat
  • 970348 2023-011
    Significant Deficiency Repeat
  • 970349 2023-004
    Material Weakness
  • 970350 2023-004
    Material Weakness
  • 970351 2023-004
    Material Weakness
  • 970352 2023-004
    Material Weakness
  • 970353 2023-004
    Material Weakness
  • 970354 2023-004
    Material Weakness
  • 970355 2023-004
    Material Weakness
  • 970356 2023-004
    Material Weakness
  • 970357 2023-004
    Material Weakness
  • 970358 2023-004
    Material Weakness

Programs in Audit

ALN Program Name Expenditures
16.575 Crime Victim Assistance $215,454
14.267 Continuum of Care Program $169,460
16.736 Transitional Housing Assistance for Victims of Domestic Violence, Dating Violence, Stalking, Or Sexual Assault $162,890
93.497 Family Violence Prevention and Services/ Sexual Assault/rape Crisis Services and Supports $103,037
16.017 Sexual Assault Services Formula Program $74,585
93.136 Injury Prevention and Control Research and State and Community Based Programs $56,938
93.671 Family Violence Prevention and Services/domestic Violence Shelter and Supportive Services $42,541
93.558 Temporary Assistance for Needy Families $30,990
16.021 Justice Systems Response to Families $30,768
97.024 Emergency Food and Shelter National Board Program $3,977